WO2022186615A1 - Antimicrobial and antifungal composition comprising rosa damascena oil - Google Patents
Antimicrobial and antifungal composition comprising rosa damascena oil Download PDFInfo
- Publication number
- WO2022186615A1 WO2022186615A1 PCT/KR2022/002983 KR2022002983W WO2022186615A1 WO 2022186615 A1 WO2022186615 A1 WO 2022186615A1 KR 2022002983 W KR2022002983 W KR 2022002983W WO 2022186615 A1 WO2022186615 A1 WO 2022186615A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- composition
- antibacterial
- antifungal
- present
- Prior art date
Links
- 239000012871 anti-fungal composition Substances 0.000 title claims abstract description 13
- 244000181025 Rosa gallica Species 0.000 title abstract description 5
- 230000000845 anti-microbial effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 42
- 241000222122 Candida albicans Species 0.000 claims abstract description 25
- 229940095731 candida albicans Drugs 0.000 claims abstract description 24
- 241000222126 [Candida] glabrata Species 0.000 claims abstract description 16
- 208000032343 candida glabrata infection Diseases 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 7
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 7
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 7
- 241000588724 Escherichia coli Species 0.000 claims abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 55
- 229940121375 antifungal agent Drugs 0.000 claims description 17
- 235000011449 Rosa Nutrition 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 7
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 76
- 235000019198 oils Nutrition 0.000 description 76
- 241000220317 Rosa Species 0.000 description 55
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 240000004533 Hesperis matronalis Species 0.000 description 17
- 235000015847 Hesperis matronalis Nutrition 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 239000001965 potato dextrose agar Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 239000006071 cream Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- -1 olive oil Chemical compound 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 5
- 239000012979 RPMI medium Substances 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 244000275012 Sesbania cannabina Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229940083663 fluconazole 2 mg/ml Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008020 pharmaceutical preservative Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/34—Rosaceae [Rose family], e.g. strawberry, hawthorn, plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3472—Compounds of undetermined constitution obtained from animals or plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/10—Preserving against microbes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Definitions
- the present invention relates to an antibacterial and antifungal composition comprising rosa damacena oil.
- Antibacterial substances kill microorganisms and are low in toxicity to humans or animals and have selective toxicity that are not inactivated by enzymes in the body. By inhibiting transport, cell wall biosynthesis, etc., it exerts an effect through a mechanism that inhibits the proliferation of microorganisms.
- the main antibacterial substances developed so far can be divided into those derived from nature, such as microorganisms and plants, and those that are chemically synthesized.
- the first antibacterial substance isolated from nature was penicillin, discovered by Alexander Fleming in 1928.
- many chemically synthesized antibacterial substances are used for the treatment of diseases caused by harmful bacteria, interest in developing antibacterial agents using naturally-derived antibacterial substances is increasing due to the increase in resistance to chemically synthesized antibacterial substances. to be.
- the present invention has been devised by the above needs and an object of the present invention is to provide a novel antibacterial and antifungal composition.
- the present invention provides an antibacterial and antifungal composition
- an antibacterial and antifungal composition comprising, as an active ingredient, Rosa damacena oil (also interchangeably named 'Bulgarian rose oil' in the specification and drawings of the present invention) as an active ingredient. .
- the effective amount of Rosa damascena oil is preferably 0.05% to 10% (v/v), but is not limited thereto.
- the effective amount of Rosa damascena oil is preferably 0.1% to 10% (v/v), but is not limited thereto.
- the composition preferably has antibacterial or antifungal activity against bacteria selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Candida glabrata.
- bacteria selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Candida glabrata.
- the present invention is not limited thereto.
- the composition preferably has a pH of 5.1 to 6.0, but is not limited thereto.
- composition of the present invention is used as a cosmetic, pharmaceutical or food composition.
- the term “oil” refers to a high-concentration natural vegetable oil extracted from a plant, and it can be extracted using steam distillation, which is a method of extracting the aromatic active ingredient of a plant with steam and cooling it with cooling water and condensing it.
- the "oil” refers to a diluted or concentrated solution of an extract obtained by extraction treatment by steam distillation of plants, a dried product obtained by drying the extract, a prepared product or purified product of the extract, or a mixture thereof, such as the extract itself and It includes extracts of all formulations that can be formed using the extract.
- composition comprising Rosa damacena oil of the present invention as an active ingredient exhibits excellent antibacterial and antifungal activity by directly affecting harmful microorganisms, and thus can be usefully used as an antibacterial and antifungal pharmaceutical composition.
- composition for antibacterial and antifungal containing Rosa damacena oil of the present invention as an active ingredient may be prepared in the form of a pharmaceutically acceptable salt.
- salts can be formed by addition of acids, for example inorganic acids (e.g. hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), organic carboxylic acids (e.g.
- Acetic acid trifluoroacetic acid, etc.
- chondroitin sulfate eg, methane, sulfonic acid, p-toluene sulfonic acid
- the antibacterial and antifungal composition of the present invention is a substance separated from a natural plant extract, and can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical preparation.
- the antibacterial and antifungal composition of the present invention can actually be administered in various oral or parenteral formulations, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants, diluents or excipients such as surfactants is prepared using Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
- Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- witepsol macrogol, tween 61, cacao butter, liurinji, glycerogelatin, and the like can be used.
- the antibacterial and antifungal composition of the present invention can be used by mixing with various pharmaceutically acceptable carriers such as physiological saline or organic solvent, and in order to increase stability or absorbency, such as glucose, sucrose or dextran
- various pharmaceutically acceptable carriers such as physiological saline or organic solvent, and in order to increase stability or absorbency, such as glucose, sucrose or dextran
- Antioxidants such as carbohydrates, ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers may be used as pharmaceuticals.
- the effective dose of the antibacterial and antifungal composition of the present invention is 001 to 10 mg/kg, preferably 01 to 1 mg/kg, and may be administered 1 to 3 times a day.
- the total effective amount of the pharmaceutical composition or the culture medium of the present invention may be administered to the patient in a single dose in the form of a bolus or by infusion for a relatively short period of time, and multiple doses (multiple does) can be administered by a fractionated treatment protocol that is administered over a long period of time. Since the concentration is determined by considering various factors such as the age and health condition of the patient as well as the route of administration and the number of treatments, the effective dosage of the patient is determined. It will be possible to determine an appropriate effective dosage according to a particular use as a pharmaceutical composition.
- the present invention provides an antibacterial and antifungal cosmetic composition comprising Rosa damacena oil as an active ingredient.
- the antibacterial and antifungal composition comprising Rosa damacena oil of the present invention as an active ingredient exhibits excellent antibacterial and antifungal activity through direct effect on harmful microorganisms, so it can be usefully used as an antibacterial and antifungal cosmetic composition.
- the cosmetic composition of the present invention includes ingredients commonly used in cosmetic compositions in addition to the Rosa damacena oil as an active ingredient, for example, antioxidants, stabilizers, solubilizers, vitamins, conventional adjuvants such as pigments and fragrances, and carriers includes
- the cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it can be prepared in the form of flexible lotion (skin), nourishing lotion (milk lotion), nourishing cream, massage cream, essential oil, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder. have.
- the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide is used as a carrier component.
- lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
- a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan.
- the formulation of the present invention is a suspension
- a liquid diluent such as water, ethanol or propylene glycol
- a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals
- cellulose aluminum metahydroxide, bentonite, agar or tragacanth
- bentonite agar or tragacanth
- the formulation of the present invention is a surfactant-containing cleansing agent
- Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.
- cosmetics of the present invention include feminine cleanser, hand sanitizer, face wash cream, face wash foam, cleansing cream, cleansing milk, cleansing lotion, massage cream, cold cream, moisture cream, emulsion, lotion, pack, after-saving cream, anti-sun cream , suntan oil, soap, body shampoo, hair shampoo, hair conditioner, hair treatment, hair conditioner, hair growth agent, hair cream, hair liquid, set lotion, hand cream, and lipstick.
- the present invention provides a food composition or feed preservation composition for antibacterial and antifungal containing Rosa damassena oil as an active ingredient.
- Food or feed preservatives are additives used to prevent deterioration, spoilage, discoloration and chemical changes of food or feed. These include sterilizing agents and antioxidants. ,Including functional antibacterial agents such as inhibiting the growth of decaying microorganisms or sterilizing in cosmetics and pharmaceuticals. Ideal conditions for these preservatives in food or feed should be non-toxic and effective even in a small amount.
- the antibacterial and antifungal food composition or feed preservation composition comprising Rosa damacena oil of the present invention as an active ingredient exhibits excellent antibacterial and antifungal activity through direct effect on harmful microorganisms. It can be widely used as preservatives and pharmaceutical preservatives.
- the present invention comprises the step of killing pathogenic bacteria by administering to an individual in need of treatment an antibacterial and antifungal composition comprising the Rosa damacena oil as an active ingredient, except for humans
- an antibacterial and antifungal composition comprising the Rosa damacena oil as an active ingredient, except for humans
- the method for treating a bacterial or fungal infection of an animal other than a human according to the present invention is a method of treating an animal other than a human, it does not mean that the treatment method is ineffective in humans.
- the treatment method in consideration of having a disease caused by a bacterial or fungal infection in which symptoms can be improved by administration of the therapeutic composition according to the present invention in the case of humans, it can be sufficiently used for human treatment.
- the term "animals other than humans” refers to horses, sheep, pigs, and goats excluding only humans having diseases caused by bacterial or fungal infection whose symptoms can be improved by administration of the therapeutic composition according to the present invention. , means animals such as cats and dogs.
- the term "administration” means introducing a predetermined substance to an animal by any suitable method, and the administration route of the therapeutic composition according to the present invention is oral or through any general route as long as it can reach the target tissue. It may be administered parenterally.
- the therapeutic composition according to the present invention may be administered by any device capable of moving the active ingredient to the target cell.
- the preferred dosage of the therapeutic composition according to the present invention varies depending on the condition and weight of the animal to be treated, the degree of disease, the drug form, the route of administration, and the duration, but may be appropriately selected by those skilled in the art.
- the pharmaceutical composition of the present invention is 0.01 to 10 mg/kg, preferably 0.1 to 1 mg/kg, and may be administered 1 to 3 times a day.
- composition of the present invention has antibacterial and antifungal effects by itself, it can be used directly as an antibacterial and antifungal composition, and can also be used in a form for mixing with other ingredients containing natural extracts having antibacterial and antifungal effects. It is expected to further enhance the existing antibacterial or antifungal effect.
- Bulgarian rose damacena oil of the present invention showed antifungal activity against Candida species including Candida glabrata and Candida albicans with a MIC and MFC of 0.25% (FIG. 3), and 0.05 % Bulgarian Rose Damasena oil induced apoptosis of 25-35% of Candida cells of two different species ( FIG. 5 ) and inhibited mycelial growth of Candida albicans cultured in RPMI medium ( FIG. 7 ).
- Bulgarian rose damacena oil exhibits antifungal activity against Candida species that can cause vaginosis, so the results of the present invention could potentially facilitate research into new alternative or complementary therapies for vaginal candidiasis.
- FIG. 1 is a figure showing the antibacterial activity of Bulgarian rose damascene oil, Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli, and Candida albicans disk diffusion analysis of Bulgarian rose damask oil against each bacteria, Alternatively, molds were spread on LB or PDA-agar plates and then 8 mm paper discs were placed on the plates and loaded with 40 ml/disk of the indicated samples. After 24 hours of incubation, the diameter of the transparent area of each plate was measured.
- Figure 2 is a figure showing the antifungal activity of Bulgarian Rose Damasena oil against Candida species, it is a disc diffusion assay of Bulgarian Rose Damascus oil against Candida species, and each Candida species is plated on a PDA-agar plate and indicated Bulgarian rose damask oil of the same concentration was applied to the paper disc and the diameter of the transparent area was measured.
- FIG 3 is a figure showing the MIC and MFC of Bulgarian rose damask oil against Candida species.
- the absorbance of the titer plate was measured at 600 nm (top panel).
- the MIC was determined as the lowest concentration of Bulgarian rose damask oil at which no visible growth was detected in the wells (lower panel).
- Figure 4 is a diagram showing the pH dependence of the antifungal effect of Bulgarian rose damacena oil in the absence (A) or presence (B) of Candida species (1x10 5 cells in 10 ⁇ L) in the absence (A) or presence (B) of the indicated concentrations of Bulgarian rose damacena oil. It was added to 90 ⁇ L of PDA medium of various pH values. After 24 h, the growth of Candida species was determined by measuring the absorbance at 600 nm. (p ⁇ 0.05:*, p ⁇ 0.01:**, p ⁇ 0.001:***)
- FIG. 5 is a diagram showing the effect of Bulgarian rose damask oil on apoptosis of Candida species at various pH levels.
- strains and reagents used in the present invention are as follows.
- Luria Broth (LB) and Potato Dextrose Broth (PDA) were purchased from Alpha Biosciences (Baltimore, MD, USA).
- Staphylococcus aureus KCTC1621, Staphylococcus epidermidis KCTC1917 and Pseudomonas aeruginosa KCTC1636 were purchased from Korean Collection for Type Cultures (KCTC, Jeongeup, Korea).
- Bacillus subtilis KACC14741 and Candida albicans strains KACC 30003 and KACC 30004 were purchased from the Korea Agricultural Microorganism Bank (KACC, Jeonju, Korea).
- E. coli DH5 ⁇ was purchased from RBC Bioscience (Taiwan).
- Candida glabrata strains KBNO6P00368 and KBNO6P00369 were obtained from Chonbuk National University Hospital (Cheongju, Korea). Gram-positive strains (Staphylococcus aureus, Bacillus subtilis, Staphylococcus epidermidis) and Gram-negative strains (Escherichia coli, Pseudomonas aeruginosa) were digested with 10 g/L of casein, 5 g/L yeast extract and 10 g/L sodium chloride in a complete liquid medium (LB ) under constant shaking (200rpm) at 37°C.
- LB complete liquid medium
- Fungi (Candida glabrata and Candida albicans) were cultured at 37 °C under constant shaking (200 rpm) in complete liquid medium (PDA) consisting of 4 g/L potato infusion and 20 g/L dextrose.
- PDA liquid medium
- the antibacterial and antifungal activity of Bulgarian rose damask oil against microorganisms was investigated by disc diffusion assay. Using the culture medium as a blank value, absorbance was measured at 600 nm with a microplate reader (Molecular devices, San Jose, CA, USA) and the number of bacteria was determined by turbidimetric analysis. Spread on LB or PDA agar plates and place a sterile 8 mm paper disc (Advantec, Tokyo, Japan) on the plate. Bulgarian rose damacena oil was dissolved in 70% ethanol at a concentration of 0 to 10% (v/v), 40 ⁇ L of each sample was applied to the disk, and the plate was incubated at 37 °C for 24 h. The area of inhibition was measured in millimeters using Vernier calipers. Ampicillin (50 mg/ml) and 70% ethanol were used as positive controls.
- Serial 2-fold dilutions of Bulgarian rose damacena oil were prepared with PDA liquid medium at concentrations ranging from 0 to 0.25%.
- Wells of a 96-well plate were filled with 50 ⁇ L/well of each dilution of Bulgarian rose damacena oil and 50 ⁇ L/well of each Candida species with a total number of 1 ⁇ 10 5 cells.
- the MIC was determined by incubating the plate at 37 °C for 24 h and measuring the absorbance at 600 nm. The MIC endpoint was taken as the lowest concentration of Bulgarian rose damask oil where no growth was detected.
- Candida spp. were cultured in PDA liquid medium (pH 5.4) and 10 ⁇ L of each culture (1x10 5 cells total) at different pH values (pH 5.1, 5.4, 5.7 and 6.0) containing 0.125% Bulgarian rose damacena oil. was mixed with 90 ⁇ L of PDA liquid medium. After 24 hours of incubation, the growth of Candida species was determined based on the optical density of the sample.
- the medium containing Candida was diluted with an equal volume of 0.4% trypan blue solution and incubated for 3 minutes at room temperature. Each sample was placed in a hemocytometer and the number of cells was counted under a microscope to determine the average number of stained cells.
- the results of the present invention showed that 1% Bulgarian rose damacena oil effectively inhibited the growth of Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Pseudomonas aeruginosa, and Escherichia coli while having an inhibitory region of 10-12 mm in diameter, thereby inhibiting the growth of Bulgarian rose damasenna oil. It has been shown to confirm antibacterial properties.
- MIC minimum inhibitory concentration
- MFC minimum bactericidal concentration
- Candida species treated with Bulgarian rose damask oil were stained with trypan blue and dead (stained) cells were counted (Fig. 5). Trypan blue staining of Candida species was not observed in PDA medium at pH 5.1 lacking essential oil. In contrast, about 25-35% of Candida glabrata and Candida albicans cells treated with 0.05% Bulgarian rose damacena oil showed trypan blue staining ( FIG. 5 ), and Bulgarian rose damacena oil showed that Candida spp. supporting the idea that it substantially induces apoptosis of This effect was greatly reduced for Candida species grown in PDA medium at pH 6.0 (Fig. 5B), supporting our claim that the antifungal activity of Bulgarian rose damacena oil is pH-dependent.
- Candida albicans can invade human epithelial and endothelial cells in the early stages of infection and can cause damage through the formation of certain morphologies such as hyphae. Therefore, the present inventors next investigated the ability of Bulgarian rose damacena oil to inhibit mycelial formation (FIG. 6).
- Candida albicans cells were cultured in RPMI medium and mycelial formation was investigated. A small number of mycelium was formed in Candida albicans cultured in RPMI without FBS, but long mycelial morphology was observed in most Candida albicans cells cultured in RPMI containing 10% FBS, a commonly used mycelial inducer. Bulgarian rose damacena oil (both 0.05% and 0.1%) completely eliminated the mycelial formation induced by 10% FBS ( FIG. 6 ), suggesting that this treatment inhibited the formation of Candida albicans mycelium.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The present invention relates to an antimicrobial and antifungal composition comprising Rosa damascena oil as an active ingredient. The composition of the present invention has antimicrobial or antifungal activities against bacteria selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Candida glabrata.
Description
본 발명은 로사 다마세나 오일을 포함하는 항균 및 항진균용 조성물에 관한 것이다.The present invention relates to an antibacterial and antifungal composition comprising rosa damacena oil.
모든 생명체는 생존을 위하여 항균 및 항진균 물질을 생산하는 것으로 알려져 있는데, 항균 및 항진균 물질을 생산하는 미생물에 대해서 많은 연구가 이루어지고 있으며, 항균 및 항진균 물질을 생산하는 미생물 또는 이들에게서 분리된 물질을 이용해 항균제 또는 항진균제를 개발하려는 연구들이 오래전부터 시도되고 있다.All living things are known to produce antibacterial and antifungal substances for survival, and many studies are being made on microorganisms that produce antibacterial and antifungal substances. Studies to develop antibacterial or antifungal agents have been attempted for a long time.
항균물질은 미생물을 죽이면서 인체 또는 동물에게는 독성이 낮고 체내의 효소 등에 의해 비활성화되지 않는 선택적 독성작용(selective toxicity)을 갖는 물질로, 이는 주로 DNA의 복제, 유전정보의 전사 및 해독, 전자에너지의 수송, 세포벽의 생합성 등을 저해함으로써 미생물의 증식을 억제하는 기전을 통해 효과를 나타낸다.Antibacterial substances kill microorganisms and are low in toxicity to humans or animals and have selective toxicity that are not inactivated by enzymes in the body. By inhibiting transport, cell wall biosynthesis, etc., it exerts an effect through a mechanism that inhibits the proliferation of microorganisms.
현재까지 개발된 주된 항균물질들은 미생물, 식물 등 천연에서 유래한 것과 화학적으로 합성된 것으로 나뉠 수 있는데, 천연에서 분리된 최초의 항균물질은 1928년 알렉산더 플레밍에 의해 발견된 페니실린이며, 이후 천연 유래 또는 화학적으로 합성된 많은 항균물질이 유해균에 의해 유발된 질병의 치료에 사용되고 있으나, 최근에는 화학적으로 합성된 항균물질에 대한 내성 증가로 인해 천연에서 유래한 항균물질을 이용한 항균제 개발에 관심이 증가하는 추세이다.The main antibacterial substances developed so far can be divided into those derived from nature, such as microorganisms and plants, and those that are chemically synthesized. The first antibacterial substance isolated from nature was penicillin, discovered by Alexander Fleming in 1928. Although many chemically synthesized antibacterial substances are used for the treatment of diseases caused by harmful bacteria, interest in developing antibacterial agents using naturally-derived antibacterial substances is increasing due to the increase in resistance to chemically synthesized antibacterial substances. to be.
천연 유래 항균 또는 항진균제와 관련된 기술로, 고삼 추출물(특허출원 제10-1993-0006319호), 자몽 추출물(특허출원 제10-1993-0006320호), 회향, 대회향, 세신, 녹나무속 식물 및 정향의 혼합 추출물(특허출원 제10-2002-0054685호), 녹차 폴리페놀 및 티트리 오일(특허출원 제10-2002-0028517호), 세스바니아 그랜디프로라 추출물(특허출원 제10-2011-0015252호) 등 다양한 식물체의 추출물 또는 그 분획물이 항균 활성을 갖는 것으로 지금까지 보고되어 있다.It is a technology related to a naturally-derived antibacterial or antifungal agent. Mixed extract (Patent Application No. 10-2002-0054685), Green Tea Polyphenol and Tea Tree Oil (Patent Application No. 10-2002-0028517), Sesbania Grandiprora Extract (Patent Application No. 10-2011-0015252) It has been reported so far that extracts of various plants or their fractions have antibacterial activity.
이러한 연구결과에도 불구하고 종래 알려진 식물추출물들은 추출 부위, 시기, 방법 등에 따라 함유된 성분들의 함량이 일정치 못하여 제제화하기 어려운 단점이 있었다. Despite these research results, conventionally known plant extracts have a disadvantage in that the content of the components contained therein is not constant depending on the extraction site, time, method, etc., and thus it is difficult to formulate it.
본 발명은 상기의 필요성에 의하여 안출된 것으로서 본 발명의 목적은 신규한 항균 및 항진균 조성물을 제공하는 것이다.The present invention has been devised by the above needs and an object of the present invention is to provide a novel antibacterial and antifungal composition.
상기의 목적을 달성하기 위하여 본 발명은 로사 다마세나 오일(본 발명의 명세서 및 도면에서 '불가리안 로즈 오일'로도 상호교환적으로 명명됨)을 유효성분으로 포함하는 항균 및 항진균용 조성물을 제공한다.In order to achieve the above object, the present invention provides an antibacterial and antifungal composition comprising, as an active ingredient, Rosa damacena oil (also interchangeably named 'Bulgarian rose oil' in the specification and drawings of the present invention) as an active ingredient. .
본 발명의 일 구현예에 있어서, 상기 조성물이 항진균 활성을 가지는 경우에 로사 다마세나 오일의 유효량은 0.05% 내지 10%(v/v)인 것이 바람직하나 이에 한정되지 아니한다.In one embodiment of the present invention, when the composition has antifungal activity, the effective amount of Rosa damascena oil is preferably 0.05% to 10% (v/v), but is not limited thereto.
본 발명의 다른 구현예에 있어서, 상기 조성물이 항균 활성을 가지는 경우에 로사 다마세나 오일의 유효량은 0.1% 내지 10%(v/v)인 것이 바람직하나 이에 한정되지 아니한다.In another embodiment of the present invention, when the composition has antibacterial activity, the effective amount of Rosa damascena oil is preferably 0.1% to 10% (v/v), but is not limited thereto.
본 발명의 또 다른 구현예에 있어서, 상기 조성물은 Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans 및 Candida glabrata로 구성된 군으로부터 선택된 균에 대한 항균 또는 항진균 활성을 가지는 것이 바람직하나 이에 한정되지 아니한다.In another embodiment of the present invention, the composition preferably has antibacterial or antifungal activity against bacteria selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Candida glabrata. However, the present invention is not limited thereto.
본 발명의 바람직한 실시예에 있어서, 상기 조성물은 pH가 5.1 내지 6.0인 것이 바람직하나 이에 한정되지 아니한다.In a preferred embodiment of the present invention, the composition preferably has a pH of 5.1 to 6.0, but is not limited thereto.
본 발명의 상기 조성물은 화장료, 의약품 또는 식품 조성물로 사용된다.The composition of the present invention is used as a cosmetic, pharmaceutical or food composition.
본 발명에서 용어 “오일”은 식물체에서 추출된 고농도의 천연 식물성 오일을 의미하며, 통상 수증기로 식물의 방향성 유효성분을 추출하고, 냉각수로 식혀 응축하는 방법인 증기 증류법을 이용하여 추출할 수 있다. 또한, 상기 "오일"은 식물의 증기 증류법에 의한 추출 처리에 의하여 얻어지는 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출액을 포함한다.In the present invention, the term “oil” refers to a high-concentration natural vegetable oil extracted from a plant, and it can be extracted using steam distillation, which is a method of extracting the aromatic active ingredient of a plant with steam and cooling it with cooling water and condensing it. In addition, the "oil" refers to a diluted or concentrated solution of an extract obtained by extraction treatment by steam distillation of plants, a dried product obtained by drying the extract, a prepared product or purified product of the extract, or a mixture thereof, such as the extract itself and It includes extracts of all formulations that can be formed using the extract.
본 발명의 로사 다마세나 오일을 유효성분으로 포함하는 조성물은 유해 미생물에 직접 영향을 미치는 것을 통해 탁월한 항균 및 항진균 활성을 나타내므로 항균 및 항진균용 약학적 조성물로 유용하게 사용될 수 있다.The composition comprising Rosa damacena oil of the present invention as an active ingredient exhibits excellent antibacterial and antifungal activity by directly affecting harmful microorganisms, and thus can be usefully used as an antibacterial and antifungal pharmaceutical composition.
한편, 본 발명의 로사 다마세나 오일을 유효성분으로 포함하는 항균 및 항진균용 조성물은 약학적으로 허용 가능한 염의 형태로 제조될 수 있다. 구체적으로 산을 첨가함으로써 염을 형성할 수 있고, 예를 들어 무기산(예: 염산, 히드로브롬산, 인산, 질산, 황산 등),유기 카르복실산(예: 아세트산, 트리플루오로아세트산과 같은 할로 아세트산, 프로피온산, 말레산, 숙신산, 말산, 시트르산, 타르타르산, 살리실산), 및 산성 당(글루쿠론산, 갈락투론산, 글루콘산, 아스코르브산), 산성 폴리사카리드(예: 히알우론산, 콘드로이틴 술페이트, 아르기닌산), 콘드로이틴 술페이트와 같은 술폰산 당 에스테르를 포함하는 유기 술폰산(예: 메탄, 술폰산, p-톨루엔 술폰산) 등을 첨가하여 염을 형성할 수 있다.On the other hand, the composition for antibacterial and antifungal containing Rosa damacena oil of the present invention as an active ingredient may be prepared in the form of a pharmaceutically acceptable salt. Specifically, salts can be formed by addition of acids, for example inorganic acids (e.g. hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), organic carboxylic acids (e.g. acetic acid, trifluoroacetic acid, etc.) Acetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), and acidic sugars (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), acidic polysaccharides such as hyaluronic acid, chondroitin sulfate, arginic acid), organic sulfonic acids including sulfonic acid sugar esters such as chondroitin sulfate (eg, methane, sulfonic acid, p-toluene sulfonic acid), etc. may be added to form salts.
본 발명의 항균 및 항진균용 조성물은 천연 식물 추출물에서 분리되는 물질로 임상투여시 경구 또는 비경구로 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있다.The antibacterial and antifungal composition of the present invention is a substance separated from a natural plant extract, and can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical preparation.
즉, 본 발명의 항균 및 항진균용 조성물은 실제로 경구 또는 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제,동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜 (Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 리우린지, 글리세로제라틴 등이 사용될 수 있다.That is, the antibacterial and antifungal composition of the present invention can actually be administered in various oral or parenteral formulations, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants, diluents or excipients such as surfactants is prepared using Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, liurinji, glycerogelatin, and the like can be used.
또한, 본 발명의 항균 및 항진균용 조성물은 생리식염수 또는 유기용매와 같이 약제로 허용된 여러 전달체(carrier)와 혼합하여 사용될 수 있고, 안정성이나 흡수성을 증가시키기 위하여 글루코스, 수크로스 또는 덱스트란과 같은 카보하이드레이트, 아스코르브 산(ascorbic acid) 또는 글루타치온과 같은 항산화제 (antioxidants), 킬레이트화제(chelating agents), 저분자 단백질 또는 다른 안정화제(stabilizers)들이 약제로 사용될 수 있다.In addition, the antibacterial and antifungal composition of the present invention can be used by mixing with various pharmaceutically acceptable carriers such as physiological saline or organic solvent, and in order to increase stability or absorbency, such as glucose, sucrose or dextran Antioxidants such as carbohydrates, ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers may be used as pharmaceuticals.
본 발명의 항균 및 항진균용 조성물의 유효용량은 001 내지 10㎎/㎏이고, 바람직하게는 01 내지 1㎎/㎏ 이며, 하루 1회 내지 3회 투여될 수 있다.The effective dose of the antibacterial and antifungal composition of the present invention is 001 to 10 mg/kg, preferably 01 to 1 mg/kg, and may be administered 1 to 3 times a day.
본 발명의 약학적 조성물에서 또는 그 배양액은 총 유효량은 볼루스(bolus) 형태 혹은 상대적으로 짧은 기간 동안 주입(infusion) 등에 의해 단일 투여량(single does)으로 환자에게 투여될 수 있으며, 다중 투여량(multiple does)이 장기간 투여되는 분할 치료 방법(fractionated treatment protocol)에 의해 투여될 수 있다. 상기 농도는 약의 투여 경로 및 치료 횟수뿐만 아니라 환자의 나이 및 건강상태 등 다양한 요인들을 고려하여 환자의 유효 투여량이 결정되는 것이므로 이러한 점을 고려할 때, 이 분야의 통상적인 지식을 가진 자라면 본 발명의 약학적 조성물로서의 특정한 용도에 따른 적절한 유효 투여량을 결정할 수 있을 것이다.The total effective amount of the pharmaceutical composition or the culture medium of the present invention may be administered to the patient in a single dose in the form of a bolus or by infusion for a relatively short period of time, and multiple doses (multiple does) can be administered by a fractionated treatment protocol that is administered over a long period of time. Since the concentration is determined by considering various factors such as the age and health condition of the patient as well as the route of administration and the number of treatments, the effective dosage of the patient is determined. It will be possible to determine an appropriate effective dosage according to a particular use as a pharmaceutical composition.
본 발명의 또 다른 양태에 따르면, 본 발명은 로사 다마세나 오일을 유효성분으로 포함하는 항균 및 항진균용 화장료 조성물을 제공한다.According to another aspect of the present invention, the present invention provides an antibacterial and antifungal cosmetic composition comprising Rosa damacena oil as an active ingredient.
본 발명의 로사 다마세나 오일을 유효성분으로 포함하는 항균 및 항진균용 조성물은 유해 미생물에 직접 영향을 미치는 것을 통해 탁월한 항균 및 항진균 활성을 나타내므로 항균 및 항진균용 화장료 조성물로 유용하게 사용될 수 있다.The antibacterial and antifungal composition comprising Rosa damacena oil of the present invention as an active ingredient exhibits excellent antibacterial and antifungal activity through direct effect on harmful microorganisms, so it can be usefully used as an antibacterial and antifungal cosmetic composition.
본 발명의 화장료 조성물은 유효성분으로 상기 로사 다마세나 오일 이외에 화장료 조성물에 통상적으로 이용되는 성분들이 포함되며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The cosmetic composition of the present invention includes ingredients commonly used in cosmetic compositions in addition to the Rosa damacena oil as an active ingredient, for example, antioxidants, stabilizers, solubilizers, vitamins, conventional adjuvants such as pigments and fragrances, and carriers includes
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수(스킨), 영양 화장수(밀크로션), 영양 크림, 맛사지 크림, 에센셜 오일, 아이크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it can be prepared in the form of flexible lotion (skin), nourishing lotion (milk lotion), nourishing cream, massage cream, essential oil, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder. have.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀,전분, 트라가칸타, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide is used as a carrier component. can be
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /may contain propellants such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제,에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라가칸타 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Adult cellulose, aluminum metahydroxide, bentonite, agar or tragacanth may be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide as carrier components Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.
본 발명의 화장품의 구체예로서는 여성청결제, 손세정제, 세안크림, 세안폼, 클렌징크림, 클렌징밀크, 클렌징로션, 마사지크림, 콜드크림, 모이스처크림, 유액, 화장수, 팩, 에프터세이빙크림, 썬텐방지크림, 썬텐용 오일,비누, 보디샴푸, 헤어샴푸, 헤어린스, 헤어트리트먼트, 양모료, 육모료, 헤어크림, 헤어리퀴드, 세트로션, 핸드크림, 및 립스틱 등을 들 수 있다.Specific examples of the cosmetics of the present invention include feminine cleanser, hand sanitizer, face wash cream, face wash foam, cleansing cream, cleansing milk, cleansing lotion, massage cream, cold cream, moisture cream, emulsion, lotion, pack, after-saving cream, anti-sun cream , suntan oil, soap, body shampoo, hair shampoo, hair conditioner, hair treatment, hair conditioner, hair growth agent, hair cream, hair liquid, set lotion, hand cream, and lipstick.
본 발명의 또 다른 양태에 따르면, 본 발명은 로사 다마세나 오일을 유효성분으로 포함하는 항균 및 항진균용 식품 조성물 또는 사료 보존 조성물을 제공한다.According to another aspect of the present invention, the present invention provides a food composition or feed preservation composition for antibacterial and antifungal containing Rosa damassena oil as an active ingredient.
식품이나 사료의 보존제는 식품이나 사료의 변질, 부패, 변색 및 화학변화를 방지하기 위해 사용되는 첨가물로서 살균제, 산화방지제가 이에 포함되며, 세균, 곰팡이, 효모 등 미생물의 증식을 억제하여 식품, 사료,화장품, 의약품 등에서 부패 미생물의 발육저지 또는 살균작용을 하는 등의 기능성 항균제도 포함된다. 이러한 식품이나 사료의 방부제의 이상적인 조건으로는 독성이 없어야 하며, 미량으로도 효과가 있어야 한다. 본 발명의 로사 다마세나 오일을 유효성분으로 포함하는 항균 및 항진균용 식품 조성물 또는 사료 보존 조성물은 유해 미생물에 직접 영향을 미치는 것을 통해 탁월한 항균 및 항진균 활성을 나타내므로 상기의 식품이나 사료의 보존제, 화장품 보존제 및 의약품 보존제 등에 폭넓게 사용될 수 있다.Food or feed preservatives are additives used to prevent deterioration, spoilage, discoloration and chemical changes of food or feed. These include sterilizing agents and antioxidants. ,Including functional antibacterial agents such as inhibiting the growth of decaying microorganisms or sterilizing in cosmetics and pharmaceuticals. Ideal conditions for these preservatives in food or feed should be non-toxic and effective even in a small amount. The antibacterial and antifungal food composition or feed preservation composition comprising Rosa damacena oil of the present invention as an active ingredient exhibits excellent antibacterial and antifungal activity through direct effect on harmful microorganisms. It can be widely used as preservatives and pharmaceutical preservatives.
본 발명의 또 다른 양태에 따르면, 본 발명은 상기 로사 다마세나 오일을 유효성분으로 포함하는 항균 및 항진균 조성물을 치료를 필요로 하는 개체에 투여하여 병원성 세균을 사멸시키는 단계를 포함하는, 인간을 제외한 동물의 세균 또는 진균성 감염 질환을 치료하는 방법을 제공한다.According to another aspect of the present invention, the present invention comprises the step of killing pathogenic bacteria by administering to an individual in need of treatment an antibacterial and antifungal composition comprising the Rosa damacena oil as an active ingredient, except for humans A method of treating a bacterial or fungal infection disease in an animal is provided.
본 발명에 따른 상기 인간을 제외한 동물의 세균 또는 진균성 감염 질환을 치료하는 방법은 비록 인간을 제외한 동물을 치료하는 방법이나, 인간에 있어 이러한 치료 방법이 효과가 없음을 의미하는 것은 아니다. 또한, 인간의 경우 있어서 본 발명에 따른 치료용 조성물의 투여에 의해 증상이 호전될 수 있는 세균 또는 진균 감염에 의한 질환을 갖는 것을 고려할 때, 인간의 치료에 있어서도 충분히 사용될 수 있다.Although the method for treating a bacterial or fungal infection of an animal other than a human according to the present invention is a method of treating an animal other than a human, it does not mean that the treatment method is ineffective in humans. In addition, in consideration of having a disease caused by a bacterial or fungal infection in which symptoms can be improved by administration of the therapeutic composition according to the present invention in the case of humans, it can be sufficiently used for human treatment.
본 발명에서 용어 "인간을 제외한 동물"은 본 발명에 따른 치료용 조성물의 투여에 의해 증상이 호전될 수 있는 세균 또는 진균의 감염에 의해 유발되는 질환을 갖는 인간만을 제외한 말, 양, 돼지, 염소, 고양이 및 개 등의 동물을 의미한다. 본 발명에 따른 치료용 조성물을 인간을 제외한 동물에게 투여함으로써, 세균 및 진균 감염에 의한 질환을 효과적으로 예방 및 치료할 수 있다.In the present invention, the term "animals other than humans" refers to horses, sheep, pigs, and goats excluding only humans having diseases caused by bacterial or fungal infection whose symptoms can be improved by administration of the therapeutic composition according to the present invention. , means animals such as cats and dogs. By administering the therapeutic composition according to the present invention to animals other than humans, it is possible to effectively prevent and treat diseases caused by bacterial and fungal infections.
본 발명에서 용어 "투여"는 어떠한 적절한 방법으로 동물에게 소정의 물질을 도입하는 것을 의미하며, 본 발명에 따른 치료용 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명에 따른 치료용 조성물은 유효성분이 표적 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다.In the present invention, the term "administration" means introducing a predetermined substance to an animal by any suitable method, and the administration route of the therapeutic composition according to the present invention is oral or through any general route as long as it can reach the target tissue. It may be administered parenterally. In addition, the therapeutic composition according to the present invention may be administered by any device capable of moving the active ingredient to the target cell.
본 발명에 따른 치료용 조성물의 바람직한 투여량은 치료 대상 동물의 상태 및 체중, 질병의 정도, 약물형태,투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 약학적 조성물은 0.01 내지 10 ㎎/㎏이고, 바람직하게는 0.1 내지 1 ㎎/㎏ 이며, 하루 1회 내지 3회 투여할 수 있다.The preferred dosage of the therapeutic composition according to the present invention varies depending on the condition and weight of the animal to be treated, the degree of disease, the drug form, the route of administration, and the duration, but may be appropriately selected by those skilled in the art. However, for a desirable effect, the pharmaceutical composition of the present invention is 0.01 to 10 mg/kg, preferably 0.1 to 1 mg/kg, and may be administered 1 to 3 times a day.
본 발명의 조성물은 그 자체적으로 항균 및 항진균 효과가 있으므로 항균 및 항진균 조성물로 바로 이용될 수 있고, 항균 및 항진균 효과가 있는 천연 추출물들을 함유하는 다른 성분과 혼합하여 사용하는 형태로도 이용이 가능하여 기존의 항균 또는 항진균 효과를 좀 더 높여줄 수 있을 것으로 기대된다.Since the composition of the present invention has antibacterial and antifungal effects by itself, it can be used directly as an antibacterial and antifungal composition, and can also be used in a form for mixing with other ingredients containing natural extracts having antibacterial and antifungal effects. It is expected to further enhance the existing antibacterial or antifungal effect.
본 발명에서 알 수 있는 바와 같이, 본 발명의 불가리안 로즈 다마세나 오일이 0.25%의 MIC 및 MFC로 Candida glabrata 및 Candida albicans를 포함한 Candida 종에 대한 항진균 활성이 있음을 보여주고(도 3), 0.05% 불가리안 로즈 다마세나 오일은 두 개의 다른 종의 칸디다 세포의 25-35%의 세포 사멸을 유도했으며(도 5), RPMI 배지에서 배양된 칸디다 알비칸스의 균사 성장을 억제했다(도 7).As can be seen from the present invention, Bulgarian rose damacena oil of the present invention showed antifungal activity against Candida species including Candida glabrata and Candida albicans with a MIC and MFC of 0.25% (FIG. 3), and 0.05 % Bulgarian Rose Damasena oil induced apoptosis of 25-35% of Candida cells of two different species ( FIG. 5 ) and inhibited mycelial growth of Candida albicans cultured in RPMI medium ( FIG. 7 ).
불가리안 로즈 다마세나 오일은 질염을 유발할 수 있는 칸디다 종에 대해 항진균 활성을 나타내어 본 발명의 결과는 잠재적으로 질 칸디다증에 대한 새로운 대안 또는 보완 요법에 대한 연구를 촉진할 수 있다.Bulgarian rose damacena oil exhibits antifungal activity against Candida species that can cause vaginosis, so the results of the present invention could potentially facilitate research into new alternative or complementary therapies for vaginal candidiasis.
도 1은 불가리안 로즈 다마세나 오일의 항균 활성을 나타낸 그림으로, Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli, 및 Candida albicans에 대한 불가리아 장미 다마스크 오일의 디스크 확산 분석이고, 각 박테리아 또는 곰팡이를 LB 또는 PDA-한천 플레이트에 펼친 후 8mm 종이 디스크를 플레이트에 놓고 표시된 샘플의 40ml/디스크로 로드했다. 24시간의 인큐베이션 후, 각 플레이트의 투명 영역의 직경을 측정했다.1 is a figure showing the antibacterial activity of Bulgarian rose damascene oil, Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli, and Candida albicans disk diffusion analysis of Bulgarian rose damask oil against each bacteria, Alternatively, molds were spread on LB or PDA-agar plates and then 8 mm paper discs were placed on the plates and loaded with 40 ml/disk of the indicated samples. After 24 hours of incubation, the diameter of the transparent area of each plate was measured.
도 2는 불가리안 로즈 다마세나 오일의 칸디다 종에 대한 항진균 활성을 나타낸 그림으로, 칸디다 종에 대한 불가리안 로즈 다마스크 오일의 디스크 확산 분석이고, 각각의 칸디다 종을 PDA-한천 플레이트에 도말하고 지시된 농도의 불가리안 로즈 다마스크 오일을 종이 디스크에 도포하고 투명 영역의 직경을 측정했다.Figure 2 is a figure showing the antifungal activity of Bulgarian Rose Damasena oil against Candida species, it is a disc diffusion assay of Bulgarian Rose Damascus oil against Candida species, and each Candida species is plated on a PDA-agar plate and indicated Bulgarian rose damask oil of the same concentration was applied to the paper disc and the diameter of the transparent area was measured.
도 3은 칸디다 종에 대한 불가리안 로즈 다마스크 오일의 MIC와 MFC를 나타낸 그림으로, (A) 칸디다 종을 표시된 농도의 불가리안 로즈 다마세나 오일을 함유하는 PDA 액체 배지에서 24시간 동안 배양하고 미세역가 플레이트의 흡광도를 600 nm(상단 패널)에서 측정했다. MIC는 웰에서 가시적인 성장이 감지되지 않는 불가리안 로즈 다마스크 오일의 최저 농도로 결정되었다(하단 패널). 3 is a figure showing the MIC and MFC of Bulgarian rose damask oil against Candida species. The absorbance of the titer plate was measured at 600 nm (top panel). The MIC was determined as the lowest concentration of Bulgarian rose damask oil at which no visible growth was detected in the wells (lower panel).
(B) 불가리안 로즈 다마세나 에센셜 오일의 MIC 측정 후, 가시적인 박테리아 성장이 없는 모든 웰의 배지를 PDA 한천 플레이트에 복제하고 24시간 배양 후 콜로니 형성을 감지했다(상단 패널). MFC는 가시적인 콜로니 형성이 감지되지 않는 불가리안 로즈 다마세나 오일의 최저 농도로 결정되었다(하단 패널).(B) After MIC measurement of Bulgarian rose damacena essential oil, the medium of all wells without visible bacterial growth was replicated on PDA agar plates and colony formation was detected after 24 h incubation (top panel). MFC was determined to be the lowest concentration of Bulgarian rose damacena oil where no visible colony formation was detected (lower panel).
도 4는 불가리안 로즈 다마세나 오일의 항진균 효과의 pH 의존성을 나타낸 그림으로, 칸디다 종(10μL 중 1x105 세포)을 표시된 농도의 불가리안 로즈 다마세나 오일의 부재(A) 또는 존재(B)에서 다양한 pH 값의 PDA 배지 90μL에 첨가했다. 24시간 후, 칸디다 종의 성장은 600 nm에서 흡광도를 측정하여 결정되었다. (p<0.05:*, p<0.01:**, p<0.001:***)Figure 4 is a diagram showing the pH dependence of the antifungal effect of Bulgarian rose damacena oil in the absence (A) or presence (B) of Candida species (1x10 5 cells in 10 μL) in the absence (A) or presence (B) of the indicated concentrations of Bulgarian rose damacena oil. It was added to 90 μL of PDA medium of various pH values. After 24 h, the growth of Candida species was determined by measuring the absorbance at 600 nm. (p<0.05:*, p<0.01:**, p<0.001:***)
도 5는 다양한 pH 수준에서 칸디다 종의 세포 사멸에 대한 불가리안 로즈 다마스크 오일의 효과를 나타낸 그림으로, 칸디다 종은 표시된 농도의 불가리안 로즈 다마세나 오일과 함께 다양한 pH 값의 PDA 배지에서 24시간 동안 배양되었다. 동일한 부피의 0.4% 트립판 블루 용액을 각 샘플에 적용하고, 염색된 세포를 혈구계산기에 로딩하고, 현미경(스케일 막대 = 5 μm, A)으로 검사하고 계수(B)하였다.5 is a diagram showing the effect of Bulgarian rose damask oil on apoptosis of Candida species at various pH levels. Candida species were treated with Bulgarian Rose Damasena oil at the indicated concentrations for 24 hours in PDA medium at various pH values. incubated during An equal volume of 0.4% trypan blue solution was applied to each sample, and the stained cells were loaded into a hemocytometer, examined under a microscope (scale bar = 5 μm, A) and counted (B).
도 6은 불가리안 로즈 다마세나 오일이 균사 발달에 미치는 영향을 나타낸 그림으로, 칸디다 종은 24시간 동안 표시된 농도의 불가리안 로즈 다마세나 오일의 존재 하에 0% 또는 10% FBS를 함유하는 RPMI 배지에서 배양되었다. 명시야 현미경 이미지가 표시됨. 스케일 바 = 20 μm.Figure 6 is a diagram showing the effect of Bulgarian Rose Damasena oil on mycelial development, Candida species in RPMI medium containing 0% or 10% FBS in the presence of the indicated concentrations of Bulgarian Rose Damacena oil for 24 hours. cultured. Brightfield microscopy images shown. Scale bar = 20 μm.
도 7은 불가리안 로즈 다마세나 오일을 처리한 칸디다 종의 세포 사멸을 나타낸 그림으로, 칸디다 종은 표시된 농도의 불가리안 로즈 다마세나 오일이 있는 RPMI 배지에서 24시간 동안 배양되었다. 샘플을 동일한 부피의 0.4% 트립판 블루 용액과 혼합하고 염색된 세포를 혈구계산기에 로딩하고 현미경(스케일 바 = 5μm, A)으로 검사하고 계수(B)하였다.Figure 7 is a picture showing the cell death of Candida species treated with Bulgarian Rose Damasena oil, Candida species were cultured for 24 hours in RPMI medium with Bulgarian Rose Damasena oil at the indicated concentration. Samples were mixed with an equal volume of 0.4% trypan blue solution and stained cells were loaded into a hemocytometer, examined under a microscope (scale bar = 5 μm, A) and counted (B).
이하 비한정적인 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 단 하기 실시예는 본 발명을 예시하기 위한 의도로 기재한 것으로서 본 발명의 범위는 하기 실시예에 의하여 제한되는 것으로 해석되지 아니한다.Hereinafter, the present invention will be described in more detail through non-limiting examples. However, the following examples are intended to illustrate the present invention, and the scope of the present invention is not to be construed as being limited by the following examples.
본 발명에서 사용된 사용균주 및 시약 등은 하기와 같다.The strains and reagents used in the present invention are as follows.
Luria Broth(LB) 및 Potato Dextrose Broth(PDA)는 Alpha Biosciences(Baltimore, MD, USA)에서 구입했다. Staphylococcus aureus KCTC1621, Staphylococcus epidermidis KCTC1917 및 Pseudomonas aeruginosa KCTC1636은 Korean Collection for Type Cultures(KCTC, 정읍, 한국)에서 구입했다. Bacillus subtilis KACC14741 및 Candida albicans 균주 KACC 30003 및 KACC 30004는 한국 농업 미생물 은행(KACC, 전주, 한국)에서 구입하였다. 대장균 DH5α는 RBC Bioscience(대만)에서 구입했다. Candida glabrata 균주 KBNO6P00368 및 KBNO6P00369는 전북대학교 병원(한국 청주)에서 입수했다. 그람 양성균주(Staphylococcus aureus, Bacillus subtilis, Staphylococcus epidermidis)와 그람음성균주(Escherichia coli, Pseudomonas aeruginosa)를 카제인의 10g/L 효소 소화, 5g/L 효모 추출물 및 10g/L 염화나트륨으로 구성된 완전액체배지(LB)에서 일정한 진탕(200rpm) 하에 37℃에서 배양하였다. 곰팡이(Candida glabrata 및 Candida albicans)를 4g/L 감자 주입 및 20g/L 덱스트로스로 구성된 완전 액체 배지(PDA)에서 일정한 진탕(200rpm) 하에 37°C에서 배양했다.Luria Broth (LB) and Potato Dextrose Broth (PDA) were purchased from Alpha Biosciences (Baltimore, MD, USA). Staphylococcus aureus KCTC1621, Staphylococcus epidermidis KCTC1917 and Pseudomonas aeruginosa KCTC1636 were purchased from Korean Collection for Type Cultures (KCTC, Jeongeup, Korea). Bacillus subtilis KACC14741 and Candida albicans strains KACC 30003 and KACC 30004 were purchased from the Korea Agricultural Microorganism Bank (KACC, Jeonju, Korea). E. coli DH5α was purchased from RBC Bioscience (Taiwan). Candida glabrata strains KBNO6P00368 and KBNO6P00369 were obtained from Chonbuk National University Hospital (Cheongju, Korea). Gram-positive strains (Staphylococcus aureus, Bacillus subtilis, Staphylococcus epidermidis) and Gram-negative strains (Escherichia coli, Pseudomonas aeruginosa) were digested with 10 g/L of casein, 5 g/L yeast extract and 10 g/L sodium chloride in a complete liquid medium (LB ) under constant shaking (200rpm) at 37°C. Fungi (Candida glabrata and Candida albicans) were cultured at 37 °C under constant shaking (200 rpm) in complete liquid medium (PDA) consisting of 4 g/L potato infusion and 20 g/L dextrose.
불가리안 로즈 다마스크 오일은 Enio Bonchev Production(불가리아 소피아 소재)에서 구입했다. Trypan blue 염료(0.4%)는 Gibco(Waltham, MA, USA)에서 구입했다. 암피실린과 플루코나졸은 Sigma-Aldrich(St. Louis, MO, USA)에서 구입했다.Bulgarian Rose Damask Oil was purchased from Enio Bonchev Production, Sofia, Bulgaria. Trypan blue dye (0.4%) was purchased from Gibco (Waltham, MA, USA). Ampicillin and fluconazole were purchased from Sigma-Aldrich (St. Louis, MO, USA).
실시예 1:디스크 확산법에 의한 항균 활성 측정Example 1: Measurement of antibacterial activity by disk diffusion method
미생물에 대한 불가리안 로즈 다마스크 오일의 항균 및 항진균 활성을 디스크 확산 분석으로 조사했다. 배양액을 블랭크 값으로 하여 마이크로플레이트 리더(Molecular devices, San Jose, CA, USA)로 600 nm에서 흡광도를 측정하여 분광광도계(turbidimetric) 분석으로 세균수를 결정한 후, 총 1x106의 미생물을 40개 μL을 LB 또는 PDA 한천 플레이트에 펼치고 멸균 8mm 종이 디스크(Advantec, Tokyo, Japan)를 플레이트 위에 놓았다. 불가리안 로즈 다마세나 오일을 70% 에탄올에 0~10%(v/v) 농도로 녹이고 각 샘플 40μL를 디스크에 도포한 후 플레이트를 37°C에서 24시간 동안 인큐베이션했다. 억제 영역은 Vernier 캘리퍼스를 사용하여 밀리미터로 측정되었다. 암피실린(50mg/ml) 및 70% 에탄올을 양성 대조군으로 사용했다. The antibacterial and antifungal activity of Bulgarian rose damask oil against microorganisms was investigated by disc diffusion assay. Using the culture medium as a blank value, absorbance was measured at 600 nm with a microplate reader (Molecular devices, San Jose, CA, USA) and the number of bacteria was determined by turbidimetric analysis. Spread on LB or PDA agar plates and place a sterile 8 mm paper disc (Advantec, Tokyo, Japan) on the plate. Bulgarian rose damacena oil was dissolved in 70% ethanol at a concentration of 0 to 10% (v/v), 40 μL of each sample was applied to the disk, and the plate was incubated at 37 °C for 24 h. The area of inhibition was measured in millimeters using Vernier calipers. Ampicillin (50 mg/ml) and 70% ethanol were used as positive controls.
실시예 2:미세액 희석법에 의한 최소 억제 농도(MIC) 측정Example 2: Determination of Minimum Inhibitory Concentration (MIC) by Microfluidic Dilution Method
0에서 0.25% 범위의 농도에서 PDA 액체 배지와 함께 불가리아 장미 다마세나 오일의 연속 2배 희석을 준비했다. 96웰 플레이트의 웰은 각각의 불가리아 장미 다마세나 오일 희석액 50μL/웰 및 총 1x105 세포 수를 갖는 각 칸디다 종의 50μL/웰로 채워졌다. 플레이트를 37°C에서 24시간 동안 인큐베이션하고 600 nm에서 흡광도를 측정하여 MIC를 결정했다. MIC 종말점은 성장이 감지되지 않는 불가리안 로즈 다마스크 오일의 가장 낮은 농도로 취했다.Serial 2-fold dilutions of Bulgarian rose damacena oil were prepared with PDA liquid medium at concentrations ranging from 0 to 0.25%. Wells of a 96-well plate were filled with 50 μL/well of each dilution of Bulgarian rose damacena oil and 50 μL/well of each Candida species with a total number of 1× 10 5 cells. The MIC was determined by incubating the plate at 37 °C for 24 h and measuring the absorbance at 600 nm. The MIC endpoint was taken as the lowest concentration of Bulgarian rose damask oil where no growth was detected.
실시예 3:최소 살균 농도(MFC) 결정Example 3: Determination of Minimum Bactericidal Concentration (MFC)
불가리안 로즈 다마세나 오일의 MIC를 측정한 후, 가시적인 박테리아 성장이 결여된 각 웰의 배지를 PDA 한천 플레이트에 복제 플레이팅하고 37°C에서 24시간 동안 인큐베이션했다. 곰팡이 개체군의 99.9%가 사멸된 최저 농도를 MFC 종말점으로 취했다.After measuring the MIC of Bulgarian rose damacena oil, the medium from each well lacking visible bacterial growth was replicate plated on PDA agar plates and incubated at 37 °C for 24 h. The lowest concentration at which 99.9% of the fungal population was killed was taken as the MFC endpoint.
실시예 4:불가리안 로즈 다마세나 오일의 항진균 활성에 대한 pH의 영향Example 4: Effect of pH on Antifungal Activity of Bulgarian Rose Damacena Oil
칸디다 종을 PDA 액체 배지(pH 5.4)에서 배양하고 각 배양액 10μL(총 1x105개 세포)를 0.125%의 불가리안 로즈 다마세나 오일을 포함하는 서로 다른 pH 값(pH 5.1, 5.4, 5.7 및 6.0)의 90μL의 PDA 액체 배지와 혼합했다. 24시간 배양 후, 샘플의 광학 밀도를 기반으로 칸디다 종의 성장을 결정했다.Candida spp. were cultured in PDA liquid medium (pH 5.4) and 10 μL of each culture (1x10 5 cells total) at different pH values (pH 5.1, 5.4, 5.7 and 6.0) containing 0.125% Bulgarian rose damacena oil. was mixed with 90 µL of PDA liquid medium. After 24 hours of incubation, the growth of Candida species was determined based on the optical density of the sample.
실시예 5: 트리판 블루 염색Example 5: Trypan Blue Staining
칸디다 균이 포함된 배지를 동일한 부피의 0.4% 트립판 블루 용액으로 희석하고 실온에서 3분 동안 인큐베이션했다. 각 샘플을 혈구계산기에 넣고 현미경으로 세포의 수를 세어 평균 염색된 세포의 수를 측정하였다.The medium containing Candida was diluted with an equal volume of 0.4% trypan blue solution and incubated for 3 minutes at room temperature. Each sample was placed in a hemocytometer and the number of cells was counted under a microscope to determine the average number of stained cells.
실시예 6:균사 성장 테스트Example 6: Mycelial Growth Test
C. albicans 종(1x105 세포/mL)을 다양한 농도의 불가리안 로즈 다마세나 오일 또는 10%(v/v) FBS의 부재 또는 존재하에 37°C에서 24시간 동안 RPMI 1640에서 37°C에서 배양했다. 각 샘플을 동일한 부피의 트립판 블루와 혼합하고 10 μL의 혼합물을 혈구계로 옮기고 균사 형성을 평가하기 위해 광학 현미경으로 관찰했다.Incubate C. albicans spp. (1x10 5 cells/mL) at 37 °C in RPMI 1640 for 24 h at 37 °C in the absence or presence of varying concentrations of Bulgarian rose damacena oil or 10% (v/v) FBS. did. Each sample was mixed with an equal volume of trypan blue and 10 μL of the mixture was transferred to a hemocytometer and observed under a light microscope to assess mycelial formation.
상기 실시예의 데이터는 각 독립 실험에 대한 평균 ± SD(표준 편차)로 표시된다. 통계 분석은 짝을 이루지 않은 스튜던트 t-검정을 사용하여 수행되었다. p < 0.05의 값은 통계적으로 유의한 차이를 나타내는 것으로 간주되었다.Data in the above examples are expressed as mean±SD (standard deviation) for each independent experiment. Statistical analysis was performed using unpaired Student's t-test. A value of p < 0.05 was considered to indicate a statistically significant difference.
상기 실시예의 결과는 하기와 같다.The results of the above examples are as follows.
불가리안 로즈 다마세나 오일의 항균 및 항진균 활성Antibacterial and Antifungal Activity of Bulgarian Rose Damacena Oil
불가리안 로즈 다마스크 오일의 항균 및 항진균 활성을 조사하기 위해 5가지 박테리아 균주와 1가지 곰팡이 균주를 사용하여 디스크 확산 분석을 수행했다(도 1). 70% 에탄올에 용해된 불가리안 로즈 다마세나 오일을 박테리아 균주에 적용하고 24시간 후에 투명 영역의 형성을 조사했다. 암피실린(최종 2mg/ml)과 70% 에탄올은 각각 그람 양성균과 그람 음성균에 대한 양성 대조군으로 사용되었다(도 1A).To investigate the antibacterial and antifungal activity of Bulgarian rose damask oil, a disc diffusion assay was performed using five bacterial strains and one fungal strain (Fig. 1). Bulgarian rose damacena oil dissolved in 70% ethanol was applied to the bacterial strains and the formation of clear areas was investigated after 24 hours. Ampicillin (final 2 mg/ml) and 70% ethanol were used as positive controls for Gram-positive and Gram-negative bacteria, respectively (FIG. 1A).
본 발명의 결과는 1% 불가리아 장미 다마세나 오일이 Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Pseudomonas aeruginosa, 및 Escherichia coli의 성장을 직경 10-12mm의 억제 영역을 가지면서 효과적으로 억제하여 불가리아 장미 다마세나 오일의 항균 특성을 확인하는 것으로 나타났다. The results of the present invention showed that 1% Bulgarian rose damacena oil effectively inhibited the growth of Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Pseudomonas aeruginosa, and Escherichia coli while having an inhibitory region of 10-12 mm in diameter, thereby inhibiting the growth of Bulgarian rose damasenna oil. It has been shown to confirm antibacterial properties.
본 발명자들은 또한 1% 불가리안 로즈 다마세나 오일이 13.5mm의 억제 영역으로 칸디다 알비칸스를 효과적으로 억제한 반면, 항균 항생제인 50mg/ml 암피실린은 칸디다 알비칸스의 성장을 억제하지 않는다는 것을 발견했다(도 1B). 이러한 결과는 불가리안 로즈 다마세나 오일이 항균 활성 외에도 항진균 활성을 가지고 있음을 시사했다.We also found that 1% Bulgarian rose damacena oil effectively inhibited Candida albicans with an inhibition area of 13.5 mm, whereas the antibacterial antibiotic 50 mg/ml ampicillin did not inhibit the growth of Candida albicans (Fig. 1B). These results suggested that Bulgarian rose damacena oil had antifungal activity in addition to antibacterial activity.
VVC의 인간 기회감염 병원체인 Candida albicans와 Candida glabrata에 대한 불가리안 로즈 다마스크 오일의 항진균 특성을 조사하기 위해(Spampinato C and Leonardi D, 2013), 2개의 Candida glabrata 균주와 2개의 Candida albicans 균주로 디스크 확산 테스트를 수행했다.(도 2). Candida glabrata KBNO6P00368의 경우, 불가리안 로즈 다마스크 오일은 0.1%에서 8.2±0.2mm, 0.5%에서 8.5±0.4mm, 1.0%에서 9.5±1.6mm, 10%에서 12.1±1.0mm의 직경으로 투명한 영역의 형성을 유도해서, 불가리안 로즈 다마세나 오일이 용량 의존적 방식으로 Candida glabrata KBNO6P00368의 성장을 억제함을 시사한다(도 2B). Candida glabrata KBNO6P00369와 Candida albicans KACC 30003 및 KACC 30004에서 유사한 결과가 얻어졌다(도 2B). 흥미롭게도 모든 시험 균주에 대한 10% 불가리안 로즈 다마스크 오일의 항진균 활성은 알려진 항진균제인 플루코나졸 2 mg/ml의 활성보다 컸다(도 2B). 이 데이터는 불가리안 로즈 다마세나 오일이 1.0% 이상의 농도에서 칸디다 종에 대해 효과적인 항진균 효과가 있음을 보여준다.To investigate the antifungal properties of Bulgarian rose damask oil against Candida albicans and Candida glabrata, human opportunistic pathogens of VVC (Spampinato C and Leonardi D, 2013), two Candida glabrata strains and two Candida albicans strains A diffusion test was performed (Fig. 2). For Candida glabrata KBNO6P00368, Bulgarian rose damask oil has a diameter of 8.2±0.2mm at 0.1%, 8.5±0.4mm at 0.5%, 9.5±1.6mm at 1.0%, and 12.1±1.0mm at 10% of the transparent area. formation, suggesting that Bulgarian rose damacena oil inhibits the growth of Candida glabrata KBNO6P00368 in a dose-dependent manner ( FIG. 2B ). Similar results were obtained for Candida glabrata KBNO6P00369 and Candida albicans KACC 30003 and KACC 30004 ( FIG. 2B ). Interestingly, the antifungal activity of 10% Bulgarian rose damask oil against all test strains was greater than that of the known antifungal agent, fluconazole 2 mg/ml (Fig. 2B). These data show that Bulgarian rose damacena oil has an effective antifungal effect against Candida species at concentrations above 1.0%.
칸디다 종에 대한 불가리안 로즈 다마스크 오일의 최소 억제 농도 및 최소 살균 농도 결정Determination of Minimum Inhibitory Concentration and Minimum Antiseptic Concentration of Bulgarian Rose Damask Oil Against Candida Species
불가리안 로즈 다마세나 오일의 항진균 가능성을 추가로 평가하기 위해 미세 희석법을 사용하여 최소 억제 농도(MIC)와 최소 살균 농도(MFC) 값을 결정했다(도 3). 불가리안 로즈 다마스크 오일의 MIC 값은 Candida glabrata와 Candida albicans에 대해 0.25%였다(도 3A). 그 후, 가시적인 박테리아 성장을 보이지 않는 모든 불가리아 장미 다마세나 오일 처리된 웰의 배지를 MFC 측정을 위해 PDA 한천 플레이트에 복제 플레이팅했다. 계산된 MFC는 Candida glabrata와 Candida albicans 모두에 대해 0.25%였다(도 3B).To further evaluate the antifungal potential of Bulgarian rose damacena oil, the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MFC) values were determined using a microdilution method (Figure 3). The MIC value of Bulgarian rose damask oil was 0.25% for Candida glabrata and Candida albicans ( FIG. 3A ). The medium of all Bulgarian rose Damasena oil-treated wells showing no visible bacterial growth was then replicate plated on PDA agar plates for MFC determination. The calculated MFC was 0.25% for both Candida glabrata and Candida albicans (Fig. 3B).
Rosa damascena 에센셜 오일의 항진균제의 PH 의존성PH dependence of antifungal drugs of Rosa damascena essential oil
천연 항균 물질의 항균 특성은 pH에 의존하는 것으로 알려져 있기 때문에, 다음으로 본 발명자들은 다양한 pH 값의 배지에서 불가리안 로즈 다마스크 오일의 항진균 활성을 조사했다(도 4). 본 발명자들의 데이터에 따르면 Candida 4종의 pH 5.1 ~ 6.0 범위에서 곰팡이 성장이 매우 유사했지만(도 4A), 불가리안 로즈 다마스크 오일의 항진균 활성은 이 pH 범위에서 다르다. 0.125%의 농도로 적용했을 때, 불가리안 로즈 다마세나 오일은 pH 6.0의 PDA 배지에 비해 pH 5.1의 PDA 배지에서 배양된 모든 칸디다 종의 성장을 더욱 효과적으로 억제했다(도 4B). 이것은 칸디다 종에 대한 불가리안 로즈 다마세나 오일의 항진균 특성이 pH 의존적이며 산성 pH에서 더 강한 것으로 보인다는 것을 시사한다.Since it is known that the antibacterial properties of natural antibacterial substances depend on the pH, the present inventors next investigated the antifungal activity of Bulgarian rose damask oil in media with various pH values (Fig. 4). According to our data, the fungal growth was very similar in the pH range of 5.1 to 6.0 of the four Candida species (Fig. 4A), but the antifungal activity of Bulgarian rose damask oil was different in this pH range. When applied at a concentration of 0.125%, Bulgarian Rose Damasena oil more effectively inhibited the growth of all Candida species cultured in PDA medium at pH 5.1 compared to PDA medium at pH 6.0 (Fig. 4B). This suggests that the antifungal properties of Bulgarian rose damacena oil against Candida species are pH dependent and appear to be stronger at acidic pH.
이 발견을 추가로 확인하기 위해 불가리안 로즈 다마스크 오일로 처리된 칸디다 종을 트리판 블루로 염색하고 죽은(염색된) 세포를 계수했다(도 5). 에센셜 오일이 결여된 pH 5.1의 PDA 배지에서는 칸디다 종의 트립판 블루 염색이 관찰되지 않았다. 대조적으로, 0.05% 불가리안 로즈 다마세나 오일로 처리된 칸디다 글라브라타 및 칸디다 알비칸스 세포의 약 25~35%가 트리판 블루 염색을 나타내(도 5), 불가리안 로즈 다마세나 오일이 칸디다 종의 세포 사멸을 실질적으로 유도한다는 아이디어를 뒷받침한다(도 5B). 이 효과는 pH 6.0의 PDA 배지에서 자란 칸디다 종에 대해 크게 감소했으며(도 5B), 불가리안 로즈 다마세나 오일의 항진균 활성이 pH 의존적이라는 본 발명자들의 주장을 뒷받침한다.To further confirm this finding, Candida species treated with Bulgarian rose damask oil were stained with trypan blue and dead (stained) cells were counted (Fig. 5). Trypan blue staining of Candida species was not observed in PDA medium at pH 5.1 lacking essential oil. In contrast, about 25-35% of Candida glabrata and Candida albicans cells treated with 0.05% Bulgarian rose damacena oil showed trypan blue staining ( FIG. 5 ), and Bulgarian rose damacena oil showed that Candida spp. supporting the idea that it substantially induces apoptosis of This effect was greatly reduced for Candida species grown in PDA medium at pH 6.0 (Fig. 5B), supporting our claim that the antifungal activity of Bulgarian rose damacena oil is pH-dependent.
Candida albicans의 균사 성장에 대한 불가리안 로즈 다마스크 오일의 억제 효과Inhibitory effect of Bulgarian rose damask oil on mycelial growth of Candida albicans
Candida albicans는 감염 초기 단계에서 인간 상피 및 내피 세포를 침투할 수 있으며 균사와 같은 특정 형태의 형성을 통해 손상을 일으킬 수 있다. 따라서 본 발명자들은 다음으로 균사 형성을 억제하는 불가리안 로즈 다마세나 오일의 능력을 조사했다(도 6). 칸디다 알비칸스 세포를 RPMI 배지에서 배양하고 균사 형성을 조사하였다. FBS가 없는 RPMI에서 배양된 Candida albicans에서는 적은 수의 균사가 형성되었지만, 일반적으로 사용되는 균사 유도물질인 10% FBS를 포함하는 RPMI에서 배양된 대부분의 Candida albicans 세포에서는 긴 균사 형태가 관찰되었다. 불가리안 로즈 다마세나 오일(0.05% 및 0.1% 모두)은 10% FBS에 의해 유도된 균사 형성을 완전히 제거했으며(도 6), 이러한 처리가 Candida albicans 균사의 형성을 억제함을 시사한다.Candida albicans can invade human epithelial and endothelial cells in the early stages of infection and can cause damage through the formation of certain morphologies such as hyphae. Therefore, the present inventors next investigated the ability of Bulgarian rose damacena oil to inhibit mycelial formation (FIG. 6). Candida albicans cells were cultured in RPMI medium and mycelial formation was investigated. A small number of mycelium was formed in Candida albicans cultured in RPMI without FBS, but long mycelial morphology was observed in most Candida albicans cells cultured in RPMI containing 10% FBS, a commonly used mycelial inducer. Bulgarian rose damacena oil (both 0.05% and 0.1%) completely eliminated the mycelial formation induced by 10% FBS ( FIG. 6 ), suggesting that this treatment inhibited the formation of Candida albicans mycelium.
RPMI 배지에서 배양된 칸디다 종을 트립판 블루로 염색한 경우(도 7), 불가리아 장미 다마스크 오일이 없는 상태에서 < 5%의 Candida glabrata 또는 Candida albicans 세포가 염색되었으며 이 비율은 불가리안 처리에 의해 농도 의존적으로 증가했다. 로즈 다마세나 오일은 불가리안 로즈 다마세나 오일로 치료하면 균사 형성을 감소시키고 세포를 죽임으로써 이 병원체의 감염성을 감소시킬 수 있음을 시사한다.When Candida species cultured in RPMI medium were stained with trypan blue (FIG. 7), <5% of Candida glabrata or Candida albicans cells were stained in the absence of Bulgarian rose damask oil, and this ratio was increased in a concentration-dependent manner. Rose damacena oil suggests that treatment with Bulgarian rose damacena oil may reduce the infectivity of this pathogen by reducing mycelial formation and killing cells.
Claims (6)
- 로사 다마세나 오일을 유효성분으로 포함하는 항균 및 항진균용 조성물.An antibacterial and antifungal composition comprising Rosa damacena oil as an active ingredient.
- 제1항에 있어서, 상기 조성물의 로사 다마세나 오일의 유효량은 0.05% 내지 10%(v/v)인 것을 특징으로 하는 항균 및 항진균용 조성물.The composition for antibacterial and antifungal according to claim 1, wherein the effective amount of Rosa damacena oil in the composition is 0.05% to 10% (v/v).
- 제1항에 있어서, 상기 조성물은 Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans 및 Candida glabrata로 구성된 군으로부터 선택된 균에 대한 항균 또는 항진균 활성을 가지는 것을 특징으로 하는 항균 및 항진균용 조성물.According to claim 1, wherein the composition is Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Candida glabrata antibacterial and antifungal activity, characterized in that it has antibacterial or antifungal activity against bacteria selected from the group consisting of for composition.
- 제1항에 있어서, 상기 조성물은 Candida albicans 및 Candida glabrata로 구성된 군으로부터 선택된 균에 대한 항균 또는 항진균 활성을 가지는 것을 특징으로 하는 항균 및 항진균용 조성물.The composition for antibacterial and antifungal according to claim 1, wherein the composition has antibacterial or antifungal activity against bacteria selected from the group consisting of Candida albicans and Candida glabrata.
- 제1항에 있어서, 상기 조성물은 pH가 5.1 내지 6.0인 것을 특징으로 하는 항균 및 항진균용 조성물.The composition for antibacterial and antifungal according to claim 1, wherein the composition has a pH of 5.1 to 6.0.
- 제1항에 있어서, 상기 조성물은 화장료, 의약품 또는 식품 조성물인 것을 특징으로 하는 항균 및 항진균용 조성물.The composition for antibacterial and antifungal according to claim 1, wherein the composition is a cosmetic, pharmaceutical or food composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020227019505A KR20220125791A (en) | 2021-03-05 | 2022-03-03 | Composition for antibacterial and antifungal containing rosa damacena oil |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0029313 | 2021-03-05 | ||
| KR20210029313 | 2021-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022186615A1 true WO2022186615A1 (en) | 2022-09-09 |
Family
ID=83155488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2022/002983 WO2022186615A1 (en) | 2021-03-05 | 2022-03-03 | Antimicrobial and antifungal composition comprising rosa damascena oil |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20220125791A (en) |
| WO (1) | WO2022186615A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005087244A1 (en) * | 2004-03-12 | 2005-09-22 | The University Of Manchester | Antimicrobial composition |
| KR20140056966A (en) * | 2012-11-02 | 2014-05-12 | 주식회사 코리아나화장품 | Fragrance composition with antiseptic activity and cosmetic composition comprising thereof |
| KR101829897B1 (en) * | 2017-01-25 | 2018-02-20 | 주식회사 아미코스메틱 | A feminine cleanser composition comprising roes damascena flower oil |
| KR101870780B1 (en) * | 2017-01-25 | 2018-06-27 | 주식회사 아미코스메틱 | A feminine cleanser composition comprising roes damascena flower oil and propolis complex extracts |
-
2022
- 2022-03-03 KR KR1020227019505A patent/KR20220125791A/en not_active Application Discontinuation
- 2022-03-03 WO PCT/KR2022/002983 patent/WO2022186615A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005087244A1 (en) * | 2004-03-12 | 2005-09-22 | The University Of Manchester | Antimicrobial composition |
| KR20140056966A (en) * | 2012-11-02 | 2014-05-12 | 주식회사 코리아나화장품 | Fragrance composition with antiseptic activity and cosmetic composition comprising thereof |
| KR101829897B1 (en) * | 2017-01-25 | 2018-02-20 | 주식회사 아미코스메틱 | A feminine cleanser composition comprising roes damascena flower oil |
| KR101870780B1 (en) * | 2017-01-25 | 2018-06-27 | 주식회사 아미코스메틱 | A feminine cleanser composition comprising roes damascena flower oil and propolis complex extracts |
Non-Patent Citations (2)
| Title |
|---|
| GHAVAM MANSUREH, AFZALI AFSANEH, MANCONI MARIA, BACCHETTA GIANLUIGI, MANCA MARIA LETIZIA: "Variability in chemical composition and antimicrobial activity of essential oil of Rosa × damascena Herrm. from mountainous regions of Iran", CHEMICAL AND BIOLOGICAL TECHNOLOGIES IN AGRICULTURE, vol. 8, no. 1, 1 December 2021 (2021-12-01), pages 1 - 16, XP055964135, DOI: 10.1186/s40538-021-00219-6 * |
| SHOHAYEB MOHAMED, EL-SAYED S. ABDEL-HAMEED, SALIH A. BAZAID , IBRAHIM MAGHRABI: "Antibacterial and Antifungal Activity of Rosa damascena MILL. Essential Oil, Different Extracts of Rose Petals", GLOBAL JOURNAL OF PHARMACOLOGY, IDOSI PUBLICATIONS, vol. 8, 1 January 2014 (2014-01-01), pages 1 - 7, XP055964130, ISSN: 1992-0075, DOI: 10.5829/idosi.gjp.2014.8.1.81275 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220125791A (en) | 2022-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11839208B2 (en) | Cannabidiol compositions and uses thereof | |
| Ogbolu et al. | In vitro antimicrobial properties of coconut oil on Candida species in Ibadan, Nigeria | |
| US7618658B2 (en) | Anti-microbial agent and anti-microbial composition | |
| KR102149973B1 (en) | Antimicrobial and Antifungal Composition Comprising Eugenol and Gallic Acid as Active Ingredient | |
| Ekom et al. | Methanol extract from the seeds of Persea americana displays antibacterial and wound healing activities in rat model | |
| Omran et al. | Evaluation of antimicrobial activity of Triphala constituents and nanoformulation | |
| WO2014019485A1 (en) | New application of pogostone | |
| KR102171948B1 (en) | Antimicrobial and Antifungal Composition Composition Comprising Mixture of Herb Essential Oil as Active Ingredient | |
| CN107735083A (en) | Bactericidal composition | |
| Jafer et al. | The biological activity of aqueous and methanolic extracts of Juglans regia on yeasts and pathologic bacteria | |
| WO2019225786A1 (en) | Antibacterial and antifungal composition comprising extract from clove, hibiscus, and coconut as effective ingredient | |
| KR20090088701A (en) | Processed magnolia extract and anti-microbial composition comprising the same | |
| KR102154252B1 (en) | Composition for Antimicrobial and Antifungal Comprising Baicalein and Wogonin as Active Ingredient | |
| WO2022186615A1 (en) | Antimicrobial and antifungal composition comprising rosa damascena oil | |
| KR101501346B1 (en) | Composition for protection or treatment of vancomycin-resistant enterococci infectious diseases comprising extract or fraction from Vitis amurensis | |
| JP2021521278A (en) | Anti-infectious disease preparation | |
| KR20130078055A (en) | Antibacterial compositions containing plant extracts or fractions | |
| KR102048525B1 (en) | Antiinflammatory, Antibacterial and Antifungal Composition containing Ulmus macrocarpa Hance and Smilax china L. Root Extract and Pharmaceutical Composition for Preventing or Treating Vaginitis, and Composition for Female Cleansing Agent containing the same | |
| KR101928211B1 (en) | Composition having inhibitory effect on microorganism and virus including enterovirus 71 causing hand-foot-mouth symptom | |
| KR20060128125A (en) | Agent for the treatment of vaginitis containing mandelic acid as an active ingradient | |
| Shabbir et al. | Effect of honey use with Seriphidium chitralense podlech on growth and biofilm formation of Pseudomonas aeruginosa | |
| N A et al. | Bioactivity of leaf and bark extractives of Prosopis africana (Guill., Perrott. and Rich.) Taub. against some multidrug-resistant microbes | |
| Sadiku et al. | Bioactivity of leaf and bark extractives of Prosopis africana (Guill., Perrott. and Rich.) Taub. against some multidrug-resistant microbes | |
| KR101219080B1 (en) | Antibacterial compositions containing Smallanthus sonchifolius extracts or fractions thereof under light intensity | |
| KR20180059296A (en) | Composition Containing Terminalia Chebula Extract and Artemisia Extract for Controlling Skin Bacterial Flora Growth, or Enhancing Skin Immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22763596 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22763596 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16/02/2024) |